Anti-HDV seroprevalence in patients with decompensated liver cirrhosis due to hepatitis B

Aim: Hepatitis B (HBV) and Hepatitis D (HDV) viruses are among the two important causes of end-stage liver disease today. In this study, we aimed to increase HDV awareness in people infected with HBV by examining the prevalence of HDV in patients with endstage liver disease due to HBV and who were evaluated for liver transplantation. Materials and Methods: The study was designed as a retrospective single-center and cross-sectional. Patients with HBV decompensated liver cirrhosis were divided into two groups as anti-HDV positive and negative. Child-turcott pugh (CTP), Model for End-Stage Liver Disease (MELD) score, complications of liver cirrhosis, viral hepatitis serology, and platelet count variables were statistically compared between the groups. Results: A total of 147 patients with decompensated liver cirrhosis due to HBV were included in the study. Anti-HDV positivity was detected in 46 (31.3%) patients, and anti-HDV negative in 101 (68.7%) patients. The mean age of HDV positive patients (48.39±9.20) was statistically significantly lower than HDV negative (54.37±7.80) patients (p

PDF

___

1. Lampertico P, Agarwal K, Berg T, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370-98.
2. Tozun N, Ozdogan O, Cakaloglu Y, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect 2015;21:1020-6.
3. Noureddin M, Gish R. Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery. Curr Gastroenterol Rep 2014;16:1-8.
4. Rizzetto M, Verme G, Recchia S, et al. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen: an active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med 1983;98:437-41.
5. Manesis EK, Papatheodoridis GV, Tiniakos DG, et al. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol 2011;55:61-8.
6. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010;7:31.
7. Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut 2000;46:420-6.
8. Romeo R, Del Ninno E, Rumi M, et al. A 28-year study of the course of hepatitis Δ infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009;136:1629-38.
9. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. The Lancet 2011;378:73-85.
10. Shen D-T, Ji D-Z, Chen H-Y, et al. Hepatitis D: not a rare disease anymore: global update for 2017–2018. Gut 2020;69:786-8.
11. Chen H-Y, Shen D-T, Ji D-Z, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut 2019;68:512-521.
12. Aribas E. Tekin B. Seroprevalence of Anti-HDV Antibody in HBsAg Positive Patients. Genel Tip Derg 2002;12:133-5.
13. Mese S, Bilek H, Gulhan B, et al. In blood donors with HBsAg positive , investigation of HDV by using serological and molecular methods. Faculty of Medicine, Medical Microbiology, specialization thesis, Diyarbakir. 2008.
14. Ozekinci T, Akpolat N, Atmaca S, et al.Testing for Total HDV Antibodies in HBsAg Positive Patients with HBV-DNA less than 5 pg/mL by Hybrid Capture . Viral Hepatitis J 2005;10:34-6.
15. Celen MK, Ayaz C, Hosoglu S, et al. Anti-hepatitis delta virus seroprevalence and risk factors in patients with hepatitis B in Southeast Turkey. Saudi Med J 2006;27:617.
16. Selcuk K, Karabey M, Gungor S, et al. Evaluation of Hepatitis D Virus serology results of Izmir Katip Celebi University Ataturk Training and Research Hospital. J Immunology and Clinical Microbiology 2019;4:91-6.
17. Eser KG. Prevalence of Hepatitis Delta in Chronic Hepatitis B Patients . Klimik J 2019;32.
18. Uzunalimoglu O, Yurdaydin C, Cetinkaya H, et al. Risk factors for hepatocellular carcinoma in Turkey. Dig Dis Sci.2001;46:1022-8.
19. Degertekin H, Yalcin K, Yakut M, et al. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int 2008;28:494-8.
20. Miao Z, Zhang S, Ou X, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. J Infect Dis 2020;221:1677-87.
21. Goyal A, Murray JM. The impact of vaccination and antiviral therapy on hepatitis B and hepatitis D epidemiology. PloS one. 2014;9:e110143.